NK Cell Therapy + Chemotherapy for Sarcoma
Trial Summary
What is the purpose of this trial?
The goal of this clinical research study is to find a recommended dose of donated NK cells that can be given along with chemotherapy to patients with advanced cancers. The safety and effects of this therapy will also be studied.
Do I need to stop my current medications to join the trial?
The trial requires that you stop taking certain medications before starting. You must be at least 2 weeks from your last chemotherapy and stop any tyrosine kinase inhibitors or targeted therapies at least 3 days before starting the trial's chemotherapy. If you're on systemic steroids, you may need to adjust your dose.
What data supports the effectiveness of the treatment NK Cell Therapy + Chemotherapy for Sarcoma?
Research shows that T-cell therapies targeting NY-ESO-1, a protein found in some sarcomas, have been effective in treating advanced soft tissue sarcomas. In a clinical trial, patients receiving a similar treatment had a 41.7% response rate, with a median progression-free survival of 7.2 months.12345
Is NK Cell Therapy + Chemotherapy for Sarcoma safe for humans?
Research shows that treatments involving NY-ESO-1-specific TCR T cells, combined with chemotherapy drugs like cyclophosphamide and fludarabine, have been tested in humans with advanced soft tissue sarcoma. These studies found no serious treatment-related side effects, indicating that the therapy is generally safe.13456
What makes the NK Cell Therapy + Chemotherapy for Sarcoma treatment unique?
This treatment is unique because it combines NK (natural killer) cells engineered to target the NY-ESO-1 protein, which is often found in sarcoma cells, with chemotherapy. This approach leverages the body's immune system to specifically attack cancer cells, potentially offering a more targeted and effective treatment compared to traditional therapies.36789
Eligibility Criteria
This trial is for people aged 16-80 with advanced sarcomas, specifically synovial or myxoid/round cell liposarcoma, who've tried at least one standard treatment without success. They must have proper liver, kidney, heart, and blood function and no serious infections or autoimmune diseases. Participants need to be HLA-A*02 positive with NY-ESO-1 expression in tumors.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepleting Chemotherapy
Participants receive lymphodepleting chemotherapy prior to NK cell infusion
Treatment
Participants receive adoptive NK cells expressing an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cyclophosphamide (Alkylating agents)
- Fludarabine phosphate (Anti-metabolites)
- NY-ESO-1 TCR/IL-15 NK (CAR T-cell Therapy)
NY-ESO-1 TCR/IL-15 NK is already approved in United States for the following indications:
- Multiple Myeloma
- Synovial Sarcoma
- Myxoid/Round Cell Liposarcoma